Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study-Reference-Cited by-同舟云学术

Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study

Published:2023-10 Issue: Volume:235 Page:115612
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Retmana Irene A.,Loos Nancy H.C.,Schinkel Alfred H.,Beijnen Jos H.,Sparidans Rolf W.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference13 articles.

1. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC;Nakajima;Clin. Cancer Res.,2022

2. European Medicines Agency, Lumykras, (2022). 〈https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras#authorisation-details-section〉 (accessed January 24, 2023).

3. ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability;Loos;Pharmacol. Res.,2022

4. Nonclinical safety profile of sotorasib, a KRASG12C-specific covalent inhibitor for the treatment of KRAS p.G12C-mutated cancer;Ishida;Int. J. Toxicol.,2021

5. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12C, are associated with renal toxicity in the Sprague Dawley rat;Werner;Toxicol. Appl. Pharmacol.,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs;Journal of Chromatography B;2023-12